Investing

Eli Lilly : LLY

LLY

Stock Data

$1,054.29

$7.90 (0.74%)

Asset Type

Common Stock

Exchange

NYSE

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - GENERAL

Eli Lilly and Company is a global leader in pharmaceuticals, focusing on discovering, developing, and marketing a wide range of human medications. With a rich history dating back to 1876 and headquartered in Indianapolis, Indiana, it offers treatments for diabetes, including a comprehensive lineup of insulin products, and type 2 diabetes medications like Jardiance and Trulicity. The company also has a strong presence in oncology, rheumatoid arthritis, dermatology, mental health, and more, with notable products such as Alimta for cancer and Cymbalta for depression. Eli Lilly collaborates with various industry partners to enhance its product offerings.

All Eli Lilly Articles

577 Articles

Lee Jackson | 11 hours ago

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More

Pre-Market Stock Futures: The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday,…

Joel South | Dec 12, 2025 at 8:10 AM EST

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025)

24/7 Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue…

Ian Cooper | Dec 11, 2025 at 10:44 AM EST

Stock Market Live December 11, 2025: S&P 500 (SPY) in the Red After Nearing Record Highs

Just yesterday, markets celebrated the latest quarter-point cut from the Federal Reserve, which lowered rates to a range of 3.5%…

William Temple | Dec 8, 2025 at 8:21 AM EST

Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump

Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets.…

Ian Cooper | Dec 2, 2025 at 10:30 AM EST

Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple

After a rough pullback, the major indices are attempting to rebound higher. Helping, not only is Bitcoin starting to rebound,…

Ian Cooper | Dec 2, 2025 at 9:20 AM EST

Stock Market Live December 2: S&P 500 (SPY) Rebounding with Tech

After a rough pullback, the major indices are attempting to rebound higher. At the moment, S&P 500 futures are up…

Rich Duprey | Nov 15, 2025 at 8:00 AM EST

Alphabet’s Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too?

Alphabet (NASDAQ:GOOG)(NASDAQ:GOOGL) dominates the search engine market with a greater than 90% share, powering billions of daily queries through Google…

Douglas A. McIntyre | Nov 14, 2025 at 4:13 PM EST

Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock

Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of…

Ian Cooper | Nov 10, 2025 at 12:45 PM EST

Wall Street is Pounding the Table Over NVDA, RUN, LLY

Markets are coming back strong. All thanks to the news that the government shutdown may soon be over, which would…

Lee Jackson | Nov 10, 2025 at 8:11 AM EST

Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More

Pre-Market Stock Futures:  The futures are trading higher as the new week begins, with most investors and traders relieved that…

Rich Duprey | Nov 3, 2025 at 10:13 AM EST

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that…

Joel South | Oct 30, 2025 at 9:25 AM EDT

Eli Lilly Blows Away Q3 Earnings Expectations

Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year…

Rich Duprey | Oct 17, 2025 at 11:05 AM EDT

Is Trump Going to Kill the GLP-1 Cash Cow?

The Boom That Built Billion-Dollar Empires GLP-1 drugs have reshaped the pharmaceutical landscape, turning obesity and diabetes treatments into massive…

Rich Duprey | Oct 13, 2025 at 6:46 AM EDT

3 Low-Risk ETFs That Smoke the S&P 500’s Long-Term Gains

Friday’s market meltdown laid bare the vulnerabilities of the S&P 500. The index plunged 2.7%, erasing weekly gains amid President…

Rich Duprey | Oct 1, 2025 at 10:47 AM EDT

100% Pharmaceutical Tariffs Are Here. Time to Buy These 3 Drugmakers

Starting today, the U.S. imposed 100% tariffs on imports of branded or patented pharmaceutical products that President Trump announced last…